Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Federal Trade Commission
Covington
Cerilliant
Chinese Patent Office
Baxter
Harvard Business School
Fuji
QuintilesIMS

Generated: February 23, 2018

DrugPatentWatch Database Preview

Millennium Pharms Company Profile

« Back to Dashboard

Summary for Millennium Pharms
International Patents:203
US Patents:11
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Millennium Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes 7,687,662 ➤ Sign Up Y Y ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-001 Nov 20, 2015 RX Yes No 8,871,745 ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes 8,546,608 ➤ Sign Up Y ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No 8,003,819 ➤ Sign Up Y Y ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No 7,687,662 ➤ Sign Up Y Y ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-003 Nov 20, 2015 RX Yes Yes 7,442,830 ➤ Sign Up Y Y ➤ Sign Up
Millennium Pharms NINLARO ixazomib citrate CAPSULE;ORAL 208462-002 Nov 20, 2015 RX Yes No 9,233,115 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Millennium Pharms

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 5,780,454*PED ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 6,617,317 ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 6,747,150 ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 7,119,080 ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 6,083,903 ➤ Sign Up
Millennium Pharms VELCADE bortezomib INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 021602-001 May 13, 2003 6,297,217 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MILLENNIUM PHARMS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe For Injection 3.5 mg/vial ➤ Subscribe 11/20/2008

Non-Orange Book US Patents for Millennium Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,175,018 Boronate ester compounds and pharmaceutical compositions thereof ➤ Sign Up
6,699,835 Formulation of boronic acid compounds ➤ Sign Up
7,576,206 Proteasome inhibitors and methods of using the same ➤ Sign Up
2,015,307,523 ➤ Sign Up
8,772,536 Proteasome inhibitors ➤ Sign Up
7,915,236 Proteasome inhibitors and methods of using the same ➤ Sign Up
7,109,323 Formulation of boronic acid compounds ➤ Sign Up
2,014,018,301 ➤ Sign Up
8,058,262 Proteasome inhibitors and methods of using the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Millennium Pharms Drugs

Country Document Number Estimated Expiration
Costa Rica 11850 ➤ Sign Up
Norway 2017016 ➤ Sign Up
China 102961387 ➤ Sign Up
Ukraine 97536 ➤ Sign Up
Taiwan I511972 ➤ Sign Up
Israel 242290 ➤ Sign Up
Netherlands 300871 ➤ Sign Up
Brazil 122014008754 ➤ Sign Up
Taiwan 201425320 ➤ Sign Up
South Korea 101690571 ➤ Sign Up
Country Document Number Estimated Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Millennium Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000025 Germany ➤ Sign Up PRODUCT NAME: LXAZOMIB UND DESSEN PHARMAZEUTISCH VERTRAEGLICHE SALZE UND ESTER WIE LXAZOMIBCITRAT; REGISTRATION NO/DATE: EU/1/16/1094 20161121
C0014 France ➤ Sign Up PRODUCT NAME: BORTEZOMIB; REGISTRATION NO/DATE: EU/1/04/274/001 20040426
C/GB04/021 United Kingdom ➤ Sign Up PRODUCT NAME: BORTEZOMIB OR PHARMACEUTICALLY ACCEPTABLE ESTER THEREOF, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/274/001 20040428
0871 Netherlands ➤ Sign Up PRODUCT NAME: IXAZOMIB EN FARMACEUTISCH AANVAARDBARE ZOUTEN EN ESTERS DAARVAN, ZOALS IXAZOMIBCITRAAT; REGISTRATION NO/DATE: EU/1/16/1094 20161123
2017 00014 Denmark ➤ Sign Up PRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123
2017010 Lithuania ➤ Sign Up PRODUCT NAME: IKSAZOMIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS IR ESTERIAI, PAVYZDZIUI KAIP IKSAZOMIBO CITRATAS; REGISTRATION NO/DATE: EU/1/16/1094 20161121
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Colorcon
Cerilliant
Healthtrust
UBS
Daiichi Sankyo
Fuji
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot